

**Patent 5,688,819**

**PATENT**

**IN UNITED STATES PATENT AND TRADEMARK OFFICE**

Patent No.: 5,688,819

Docket No: 16955DIV2CIP

Issue Date: November 18, 1997

Patentee: David F. Woodward et al.

Title NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR  
ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS

Confirmation No.: 8086

FILED ELECTRONICALLY

---

**REQUEST FOR CERTIFICATION OF CORRECTION**

Attn: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text of the Certificate in the suggested form are enclosed.

Pursuant to 1.20(a), the examiner is authorized to charge the Certificate of Correction fee of **\$100.00** to the Deposit Account No. **010885**.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

The Examiner is authorized to charge any additional fees or credit overpayment to Deposit Account No. **010885**.

Respectfully submitted,

Date: 05/24/07

By: /Brent A. Johnson/  
Brent A. Johnson, Reg. No. 51,851  
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714/246-4348  
Facsimile: 714/246-4249

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: David F. Woodward et al.

Examiner: Till, Mary C

Patent No.: 5,688,819

Group Art Unit: 1616

Issue Date: November 18, 1997

Docket No: 16955DIV2CIP

Title: NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL  
DERIVATIVES AS THERAPEUTIC AGENTS

Confirmation No.: 8086

FILED ELECTRONICALLY

Attn: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

We are transmitting herewith the attached:

- ☒ Authorization to charge the Certificate of Correction fee of \$100.00 to the Deposit Account No. **010885**
- ☒ Request for Certificate of Correction.
- ☒ Certificate of Correction Form - PTO-1050 (in duplicate)

**Please charge any additional fees or credit overpayment to Deposit Account No. 010885.**

Respectfully submitted,

Date: 05/24/07

By: /Brent A. Johnson/  
Brent A. Johnson, Reg. No. 51,851  
Agent of Record

Please send all inquiries and correspondence to:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone: 714/246-4348  
Facsimile: 714/246-4249

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 5,688,819

DATED : November 18, 1997

INVENTOR(S) : Woodward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the face page, in field (54), in "Title", in column 1, line 1, before "CYCLOPENTANE" insert - - NON-ACIDIC - -.

On the face page, in field (56), under "Other Publications", in column 2, line 3, delete "Spiroocyclic" and insert - - Spirocyclic - -, therefor.

On the face page, in field (56), under "Other Publications", in column 2, line 6, delete "Clercqet al" and insert - - Clercqet et al. - -, therefor.

On the face page, in field (56), under "Other Publications", in column 2, line 6, delete "Cyclopentanones-VXI" and insert - - Cyclopentenones-XVI - -, therefor.

On the face page, in field (56), under "Other Publications", in column 2, line 23, delete "Glaucoma," and insert - - Glaucoma", - -, therefor.

In column 1, line 1, before "CYCLOPENTANE" insert - - NON-ACIDIC - -.

In column 1, line 5, delete "CROSSREFERENCE" and insert - - CROSS-REFERENCE - -, therefor.

In column 4, line 40, after "configuration" insert - - . - -.

In column 6, line 37, delete "cydopentane" and insert - - cyclopentane - -, therefor.

In column 6, line 38, delete "a" and insert - -  $\alpha$  - -, therefor.

In column 6, line 48, delete "acydic" and insert - - acyclic - -, therefor.

MAILING ADDRESS OF SENDER:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. \_\_\_\_\_ 5,688,819 \_\_\_\_\_

Atty Docket No: 16955DIV2CIP

No. of additional copies



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 5,688,819  
DATED : November 18, 1997  
INVENTOR(S) : Woodward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 7, line 12, delete "3- $\alpha$ hydroxy" and insert - - 3 $\alpha$ -hydroxy - -, therefor.

In column 7, line 14, delete "3- $\alpha$ hydroxy" and insert - - 3 $\alpha$ -hydroxy - -, therefor.

In column 7, line 15, delete "1<sub>60</sub>" and insert - - 1 $\alpha$  - -, therefor.

In column 7, line 18, delete "cydopentane" and insert - - cyclopentane - -, therefor.

In column 7, line 23, delete "5<sub>d</sub>," and insert - - 5<sub>d</sub>] - -, therefor.

In column 7, line 25, delete "5<sub>6a</sub>" and insert - - 5 $\alpha$  - -, therefor.

In column 7, line 26, delete "cydopentane" and insert - - cyclopentane - -, therefor.

In column 7, line 53, delete "cydopentane" and insert - - cyclopentane - -, therefor.

In column 7, line 57, after "5<sub>d</sub>]" insert - - . - -.

In column 8, line 29, delete "tonidty" and insert - - tonicity - -, therefor.

In column 9, line 28, delete "dihydroxy;" and insert - - dihydroxy, - -, therefor.

In column 10, line 9, delete "[1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ]" and insert - - [1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ] - -, therefor.

In column 10, line 17, delete "[1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ]" and insert - - [1 $\alpha$ ,2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ] - -, therefor.

In column 11, line 23, delete "suface" and insert - - surface - -, therefor.

MAILING ADDRESS OF SENDER:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. \_\_\_\_\_ 5,688,819 \_\_\_\_\_

Atty Docket No: 16955DIV2CIP

No. of additional copies



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 5,688,819  
DATED : November 18, 1997  
INVENTOR(S) : Woodward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 11, line 53, delete "petroatum" and insert - - petrolatum - -, therefor.

In column 12, line 20, delete "caldum" and insert - - calcium - -, therefor.

In column 13, line 30, in Claim 1, delete "-OR<sup>4</sup>" and insert - - of -OR<sup>4</sup> - -, therefor.

In column 13, line 39, in Claim 1, delete "Y" and insert - - Y<sup>1</sup> - -, therefor.

In column 13, line 65, in Claim 5, delete "or" and insert - - of - -, therefor.

In column 14, line 65, in Claim 10, delete "hepteneamide" and insert - - heptenamide - -, therefor.

In column 15, line 42, in Claim 11, delete "or" and insert - - of - -, therefor.

In column 15, line 66, in Claim 12, after "compound" insert - - is - -.

In column 16, line 12, in Claim 12, delete "hydroxy,." and insert - - hydroxy, - -, therefor.

In column 16, line 17, in Claim 13, delete "III." and insert - - III - -, therefor.

In column 16, line 29, in Claim 14, delete "IV." and insert - - IV - -, therefor.

In column 16, line 40, in Claim 15, after "compound is" delete "a".

In column 17, line 16, in Claim 18, delete "[1<sub>a</sub>,2<sub>b</sub>,3<sub>a</sub>,5<sub>a</sub>]" and insert - - [1<sub>α</sub>,2<sub>β</sub>,3<sub>α</sub>,5<sub>α</sub>] - -, therefor.

MAILING ADDRESS OF SENDER:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. \_\_\_\_\_ 5,688,819 \_\_\_\_\_

Atty Docket No: 16955DIV2CIP

No. of additional copies



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 5,688,819

DATED : November 18, 1997

INVENTOR(S) : Woodward et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 17, line 24, in Claim 18, delete "pentenyl-3" and insert - - pentenyl)-3 - -, therefor.

In column 18, line 22, in Claim 20, delete "heptenonic" and insert - - heptenoic - -, therefor.

MAILING ADDRESS OF SENDER:

Brent A. Johnson  
Allergan, Inc. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612

PATENT NO. \_\_\_\_\_ 5,688,819 \_\_\_\_\_

Atty Docket No: 16955DIV2CIP

No. of additional copies

